437 related articles for article (PubMed ID: 28571533)
21. Blocking oncogenic Ras signaling for cancer therapy.
Adjei AA
J Natl Cancer Inst; 2001 Jul; 93(14):1062-74. PubMed ID: 11459867
[TBL] [Abstract][Full Text] [Related]
22. Influencing cellular transformation by modulating the rates of GTP hydrolysis by Cdc42.
Fidyk N; Wang JB; Cerione RA
Biochemistry; 2006 Jun; 45(25):7750-62. PubMed ID: 16784226
[TBL] [Abstract][Full Text] [Related]
23. K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2017 Jan; 125():299-314. PubMed ID: 27688185
[TBL] [Abstract][Full Text] [Related]
24. The guanine nucleotide exchange factor Tiam1: a Janus-faced molecule in cellular signaling.
Boissier P; Huynh-Do U
Cell Signal; 2014 Mar; 26(3):483-91. PubMed ID: 24308970
[TBL] [Abstract][Full Text] [Related]
25. Role of Rho GTPases in breast cancer.
Tang Y; Olufemi L; Wang MT; Nie D
Front Biosci; 2008 Jan; 13():759-76. PubMed ID: 17981586
[TBL] [Abstract][Full Text] [Related]
26. K-Ras protein as a drug target.
McCormick F
J Mol Med (Berl); 2016 Mar; 94(3):253-8. PubMed ID: 26960760
[TBL] [Abstract][Full Text] [Related]
27. KSR as a therapeutic target for Ras-dependent cancers.
Neilsen BK; Frodyma DE; Lewis RE; Fisher KW
Expert Opin Ther Targets; 2017 May; 21(5):499-509. PubMed ID: 28333549
[TBL] [Abstract][Full Text] [Related]
28. Essential role of Cdc42 in Ras-induced transformation revealed by gene targeting.
Stengel KR; Zheng Y
PLoS One; 2012; 7(6):e37317. PubMed ID: 22719838
[TBL] [Abstract][Full Text] [Related]
29. Direct inhibition of RAS: Quest for the Holy Grail?
Spencer-Smith R; O'Bryan JP
Semin Cancer Biol; 2019 Feb; 54():138-148. PubMed ID: 29248537
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological strategies to target oncogenic KRAS signaling in pancreatic cancer.
Chuang HC; Huang PH; Kulp SK; Chen CS
Pharmacol Res; 2017 Mar; 117():370-376. PubMed ID: 28077300
[TBL] [Abstract][Full Text] [Related]
31. Targeting RAS signalling pathways in cancer therapy.
Downward J
Nat Rev Cancer; 2003 Jan; 3(1):11-22. PubMed ID: 12509763
[TBL] [Abstract][Full Text] [Related]
32. Recent advances in cancer drug discovery targeting RAS.
Wilson CY; Tolias P
Drug Discov Today; 2016 Dec; 21(12):1915-1919. PubMed ID: 27506872
[TBL] [Abstract][Full Text] [Related]
33. Cdc42: Role in Cancer Management.
Qadir MI; Parveen A; Ali M
Chem Biol Drug Des; 2015 Oct; 86(4):432-9. PubMed ID: 25777055
[TBL] [Abstract][Full Text] [Related]
34. The CDC42-specific inhibitor derived from ACK-1 blocks v-Ha-Ras-induced transformation.
Nur-E-Kamal MS; Kamal JM; Qureshi MM; Maruta H
Oncogene; 1999 Dec; 18(54):7787-93. PubMed ID: 10618719
[TBL] [Abstract][Full Text] [Related]
35. RAS: target for cancer therapy.
Saxena N; Lahiri SS; Hambarde S; Tripathi RP
Cancer Invest; 2008 Nov; 26(9):948-55. PubMed ID: 18798058
[TBL] [Abstract][Full Text] [Related]
36. Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view.
Lu S; Jang H; Gu S; Zhang J; Nussinov R
Chem Soc Rev; 2016 Sep; 45(18):4929-52. PubMed ID: 27396271
[TBL] [Abstract][Full Text] [Related]
37. Molecular subversion of Cdc42 signalling in cancer.
Murphy NP; Binti Ahmad Mokhtar AM; Mott HR; Owen D
Biochem Soc Trans; 2021 Jun; 49(3):1425-1442. PubMed ID: 34196668
[TBL] [Abstract][Full Text] [Related]
38. Biomarkers downstream of RAS: a search for robust transcriptional targets.
Györffy B; Schäfer R
Curr Cancer Drug Targets; 2010 Dec; 10(8):858-68. PubMed ID: 20718707
[TBL] [Abstract][Full Text] [Related]
39. Molecular pathways: targeting the kinase effectors of RHO-family GTPases.
Prudnikova TY; Rawat SJ; Chernoff J
Clin Cancer Res; 2015 Jan; 21(1):24-9. PubMed ID: 25336694
[TBL] [Abstract][Full Text] [Related]
40. [Progress in the study of antitumor drug targeting on the Ras signaling pathway].
Zhu YJ; Jiang FC
Yao Xue Xue Bao; 2009 Jan; 44(1):1-10. PubMed ID: 19350814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
